Literature DB >> 19095293

Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriatic arthritis: a pilot study.

Stephanie W Hu1, Elizabeth W Holt, M Elaine Husni, Abrar A Qureshi.   

Abstract

OBJECTIVES: Psoriatic arthritis (PsA) is a seronegative inflammatory arthritis found in up to 5 to 42% of patients with psoriasis. As current instruments do not fully capture health-related quality of life (HR-QOL) in PsA from the patient's perspective, we piloted a novel application of "willingness-to-pay" (WTP) as a Patient Reported Outcome to measure the relative impact of PsA in 8 domains of HR-QOL.
METHODS: Fifty-nine PsA patients were interviewed on 8 WTP HR-QOL domains (physical, emotional, sleep, work, social, self-care, intimacy, and concentration). Participants were asked to rank the 8 domains of health in order of HR-QOL impact. In each domain, participants were asked whether PsA affected that domain, whether they were willing to pay for a cure in that domain, and the amount they were willing to pay. Median WTP amounts were compared with the proportion of participants affected by and willing to pay in each domain. Responses in US dollars were interpreted as strength of preference rather than absolute monetary values.
RESULTS: The majority of participants were white (98%), > or =45 years of age (70%), insured (98%), and earned >$65,000/yr (66%). The physical domain was most affected by PsA; intimacy and concentration were ranked lowest. Participants reported a wide range of WTP amounts ($0 to $1,000,000), and median WTP amounts were highest in the physical, work, sleep, and self-care domains. Related domains elicited median WTP amounts that were highly correlated. No significant differences in median WTP amounts were found across ages, genders, and income levels for the different domains.
CONCLUSIONS: WTP is a novel quantitative patient-perspective measure that is comprehensible and feasible to administer in PsA patients. It represents a unique tool for capturing the complex manifestations of PsA and its impact on the individual, allowing the quantification of specific HR-QOL parameters and providing the potential for comparison across various disease processes in a given individual. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2008        PMID: 19095293     DOI: 10.1016/j.semarthrit.2008.10.005

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  9 in total

1.  Willingness to pay as patient preference to bariatric surgery.

Authors:  Cristina Khawali; Marcos B Ferraz; Maria T Zanella; Sandra R G Ferreira
Journal:  Health Expect       Date:  2011-11-10       Impact factor: 3.377

2.  The burden of psoriatic arthritis: a literature review from a global health systems perspective.

Authors:  Seina Lee; Alan Mendelsohn; Evelyn Sarnes
Journal:  P T       Date:  2010-12

Review 3.  Impact of psoriatic arthritis on the patient: through the lens of the WHO International Classification of Functioning, Health, and Disability.

Authors:  William J Taylor
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

Review 4.  Sleep Disorders and Psoriasis: An Update.

Authors:  Bruno Halioua; Clara Chelli; Laurent Misery; Jonathan Taieb; Charles Taieb
Journal:  Acta Derm Venereol       Date:  2022-04-27       Impact factor: 3.875

Review 5.  Measurement, Classification and Evaluation of Sleep Disturbance in Psoriasis: A Systematic Review.

Authors:  Alasdair L Henry; Simon D Kyle; Sahil Bhandari; Anna Chisholm; Christopher E M Griffiths; Christine Bundy
Journal:  PLoS One       Date:  2016-06-21       Impact factor: 3.240

6.  Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness-to-Pay Approach.

Authors:  Casper Webers; Ivette Essers; Astrid van Tubergen; Jürgen Braun; Frank Heldmann; Xenofon Baraliakos; Annelies Boonen
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-02-18       Impact factor: 4.794

7.  Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative.

Authors:  Giorgio L Colombo; Sergio Di Matteo; Chiara Martinotti; Steffen M Jugl; Praveen Gunda; Mariantonietta Naclerio; Giacomo M Bruno
Journal:  Clinicoecon Outcomes Res       Date:  2018-08-30

8.  Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity in patients with psoriatic arthritis.

Authors:  Jane T Osterhaus; Oana Purcaru
Journal:  Arthritis Res Ther       Date:  2014-07-04       Impact factor: 5.156

9.  Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study.

Authors:  A Kavanaugh; D Gladman; D van der Heijde; O Purcaru; P Mease
Journal:  Ann Rheum Dis       Date:  2014-06-18       Impact factor: 19.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.